International Journal of Cardiovascular Diseases & Diagnosis

Review Article

Association of Heart Failure and COVID-19

Reviandy Achmad Armandani*

Ngudi Waluyo Wlingi Regional Public Hospital, Blitar District, Indonesia

***Address for Correspondence:** Reviandy Achmad Armandani, Ngudi Waluyo Wlingi Regional Public Hospital, Blitar District, Indonesia, E-mail: andyarmandani@gmail.com

Submitted: 21 March 2022; **Approved:** 28 March 2022; **Published:** 29 March 2022

Cite this article: Armandani RA. Association of Heart Failure and COVID-19. Int J Cardiovasc Dis Diagn. 2022 Mar 29;7(1): 001-008.

ISSN: 2689-4718

ABSTRACT

Introduction: A near and captivating relationship has been proposed between Heart Failure (HF) and coronavirus illness 2019 (COVID-19). To begin with, COVID-19 widespread spoken to a worldwide open wellbeing crisis within the final year and had a disastrous affect on wellbeing frameworks around the world. A few thinks about appeared a decrease in HF hospitalizations, extending from 30 to 66% in numerous nations and leading to ensuing increment in HF mortality. Moment, pre-existing HF could be a hazard calculate for a more extreme clinical course of COVID-19 and free indicator of in-hospital mortality. Then, patients hospitalized for COVID-19 may create both an intense decompensation of inveterate HF and de-novo HF as a result of myocardial harm and Cardiovascular (CV) complications. Myocardial harm happened in at slightest 10% of unselected COVID-19 cases and up to 41% in fundamentally sick patients or in those with concomitant CV comorbidities. Few cases of COVID-19-related intense myocarditis, displaying with serious decrease.

Methods: This study using systematic review that search using keyword heart failure and Covid-19 in Google Scholar, PubMed, and CrossRef. After final screening the author analysize 4 articles.

Results: An outline of accessible information and the potential components behind myocardial damage, conceivably driving to HF, will be displayed in this audit.

Conclusion: Past the intense stage, HF as a conceivable long-term result of cardiac association in COVID-19 patients has been assumed and got to be explored however.

Keywords: Heart failure; COVID-19

INTRODUCTION

Coronavirus Infection 2019 (COVID-19) quickly spread around the world getting to be a worldwide open wellbeing crisis. It is caused by a novel encompassed, emphatically stranded RNA beta coronavirus named serious intense respiratory disorder coronavirus 2 (SARS-CoV-2) [1]. So distant, more than one hundred million of affirmed COVID-19 cases can be checked around the world, with a add up to of more than three million passings, as of June 1, 2021, concurring to the World Health Organization [2]. Although COVID-19 was at first considered a respiratory illness, it has quickly ended up clear that a multiorgan association was common. In specific, the heart frequently speaks to a target organ and patients may create Heart Failure (HF) [3-6].

The interface between COVID-19 and HF is more complex. To begin with, COVID-19 widespread has an affect on HF administration and a lessening of hospitalizations due to HF has been appeared amid the widespread period, conceivably driving to an increment in HF mortality. Moment, history of HF may be a chance calculate for a more serious clinical course of COVID-19. Third, HF can be a result of COVID-19-related myocardial damage. The point of this survey is to depict the the study of disease transmission of HF amid the widespread, the part of cardiac harm and HF in COVID-19 and its pathogenetic instruments.

METHODS

This study using systematic review that search using keyword Heart failure and COVID-19 in Google Scholar, PubMed, and CrossRef. After final screening the author analysize 4 articles. As in methods, the author summarize 4 articles that mention in figure 1.

DISCUSSION

Heart failure may be a clinical disorder that results when the heart is incapable to supply adequate blood stream to meet metabolic necessities or oblige systemic venous return. This common condition influences over 5 million individuals within the Joined together States at a fetched of $10-38 billion per year [7].

Heart failure comes about from harm to the myocardium from a assortment of causes counting ischemic heart illness, hypertension, and diabetes. Less common etiologies incorporate cardiomyopathies, valvular illness, myocarditis, contaminations, systemic poisons, and cardiotoxic drugs. As the heart falls flat, patients create indications which incorporate dyspnea from pneumonic blockage, and fringe edema and ascites from disabled venous return. Protected indications such as queasiness, need of craving, and weakness are moreover common [8].

There are a few compensatory instruments that happen as the falling flat heart endeavors to preserve satisfactory work. These incorporate expanding cardiac yield by means of the Frank-Starling component, expanding ventricular volume and divider thickness through ventricular remodeling, and keeping up tissue perfusion with increased cruel blood vessel weight through enactment of neuro-hormonal systems. Although at first advantageous within the early stages of heart failure, all of these compensatory instruments inevitably lead to a horrendous cycle of compounding heart failure [7, 10-12].

COVID-19 widespread upsets the the study



Figure 1: Screening flow chart for systematic review.

of disease transmission and the administration of intense HF. Pressing Cardiovascular (CV) healing center confirmation appeared a common decrease amid the widespread period, with moreover a delay in critical care and an expanded chance of complications [7,8]. Additionally, a few considers detailed a decrease in HF hospitalizations extending from 30 to 66% [9-13]. An investigation from a tertiary Heart failureUnit in London appeared that the number of HF hospitalizations had a critical decay by 66% amid the COVID-19 widespread, compared both with a pre-COVID period within the same year and the comparing time periods from 2017 to 2019 [9].

The clinical introduction and the course of COVID-19 is amazingly variable, extending from an asymptomatic or pauci-symptomatic sickness, displaying with gentle indications (e.g., fever, dry hack, and weakness), to an extreme illness [e.g., extreme pneumonia and intense respiratory trouble disorder (ARDS)] with conceivably lethal result [14-18]. The most punctual reports from China and Italy appeared a tall predominance of comorbidities and their affiliation with the seriousness of COVID-19 and expanded mortality [19-21]. In a report of 72,314 cases, the by and large case-fatality rate of COVID-19 was 2.3%, with higher rates in patients with pre-existing comorbidities [10.5, 7.3, 6.3, and 6.0% in patients with Cardiovascular Infection (CVD), diabetes, constant respiratory malady, and hypertension, separately] [22]. A more later meta-analysis recommended that CVD and cardiovascular hazard variables (hypertension and diabetes) were closely related to lethal results in COVID-19 patients, over and freely from all ages [23-25].

Association of heart failure and COVID-19

The pathogenesis of myocardial harm in COVID-19 is still not totally clear and likely includes different pathways. In general, myocardial harm can be summarized recognizing two diverse components of harm: the primary, "indirect" or "aspecific," common with other extreme contaminations, and the moment, "direct" or "specific," related to the impossible to miss impacts intervened by SARS-CoV-2 [24-28].

To begin with, COVID-19 has common harmful impacts on the cardiovascular framework, which were as of now portrayed in other contaminations (i.e., flu and community-acquired pneumoniae). Fever and thoughtful actuation cause tachycardia with a ensuing increment in myocardial oxygen utilization [29-31]. In addition, delayed bed rest and systemic aggravation favor coagulation disarranges. Both venous and unordinary blood vessel thromboembolic occasions were watched in COVID-19 patients [32,33]. Hypoxemia, another trademark of COVID-19, is related with improved oxidative push with receptive oxygen species generation and ensuing intracellular acidosis, mitochondrial harm and cell passing [29,34].

A moment arrangement of backhanded instruments are those related with the impossible to miss unusual provocative reaction that COVID-19 may inspire: the nearness of a pro-inflammatory surge, the so-called cytokine and is thought to be central within the pathogenesis of the acute lung injury/ARDS range, because it is detailed in extremely sick patients [35,36]. Undoubtedly, amid the intense stage of the contamination, an imbalanced reaction of sorts 1 and 2 T partner cells may lead to a hyperinflammatory reaction [35,36], coming about in an over the top discharge of cytokines: in specific, higher levels of interleukin-1β (IL-1β), interleukin-6, interferon-γ, Tumor Rot Figure (TRF), macrophage incendiary protein, and Vascular Endothelial development calculate (VEGF) have been depicted in patients influenced by serious COVID-19 [16-18], and are autonomously related with a extreme course of the disease and inevitably passing [16,37].

In expansion, the hyperinflammation disorder appears to be significant within the advancement of cardiac harm, since a positive relationship has been portrayed between the increment in provocative markers and myocardial harm in COVID-19 [38-41]. Reliably, past in-vitro ponders have appeared that the discharge of proinflammatory cytokines such as TNF and IL-1β, in other septic conditions, were dependable for myocardial cells discouragement [42-44], through tweak of calcium channel movement and nitric oxide generation [43,44].

Cytokine storm may be as well the cause of intense HF: the fiery enactment and oxidative push are additionally display in HF and may incline, combined with COVID-19, to a more serious clinical course [45-47]. At long last, the checked incendiary reaction takes put too within the endothelium, as illustrated by autopsy histological discoveries appearing lymphocytic endotheliitis with apoptotic bodies and viral incorporation structures in different organs [48,49]. Endotheliitis can lead to dispersed intravascular coagulation with little or huge vessels thrombosis and dead tissue and noteworthy modern vessel development through a component of intussusceptive angiogenesis [49,50].

Thus, anti-inflammatory treatments and thromboprophylaxis have been the basically considered drugs for COVID-19 [51-54]. Dexamethasone was found to be related with lower 28-day mortality within the controlled, open-label randomized assessment of COVID-19 treatment (Recuperation) trial [51]. Useful impacts were restricted to those patients getting ventilatory bolster (either obtrusive or non-invasive), whereas unbiased impacts were detailed among patients not requiring oxygen treatment. The viability of steroids was affirmed in advance review arrangement and in one meta-analysis of seven randomized trials, counting 1,703 patients [53] (Table 1).

At long last, drugs that have been utilized as COVID-19 treatment may cause themselves myocardial damage. At the starting of the widespread, numerous drugs were proposed in an sped up way [55]. Hydroxychloroquine was at first proposed as an viable medicate for the treatment of COVID-19. It is known that hydroxychloroquine has cardiovascular poisonous quality, because it may cause arrhythmias and heart failure [56]. A later meta-analysis, counting a add up to of 5,652 COVID-19 patients, appeared that treatment with hydroxychloroquine or chloroquine was related with chance of drug-induced QT prolongation and higher rate of torsades de pointes, ventricular tachycardia, or cardiac capture [57], whereas no efficacy was found within the treatment of hospitalized patients with COVID-19 for hydroxy-chloroquine within the Recuperation trial [58]. Essentially, azithromycin was at first prescribed in patients with COVID-19, but it may increment the chance of unfavorable CV occasions (tall hazard of QTc prolongation, particularly when managed concomitantly with hydroxychloroquine [59]. A few antiviral drugs are known to cause mitochondrial brokenness and cardiotoxicity [60,61].

Angiotensin-Converting chemical (ACE)2 is the key to get it the results of SARS-CoV-2 disease on the CV framework. ACE2 may be a membrane protein, that's profoundly communicated completely different organs, counting heart, lungs, intestine, and kidneys. It

Table 1: Summerize association HF among COVID-19 patients.

Author	Origin	Method	Sample Size and Population	Period	Result	Outcome
Juan R. Rey	Spain	Retrospective study	Total sample are 3080	2020	Patients with COVID-19 have a noteworthy rate of AHF, which is related with exceptionally tall mortality rates. Additionally, patients with a history of CHF are inclined to creating intense decompensation after a COVID-19 conclusion. The withdrawal of GDMT was related with higher mortality.	The withdrawal of beta-blockers, mineralocorticoid receptor opponents and angiotensin-converting protein inhibitors or angiotensin receptor blockers was related with a noteworthy increment in in-hospital mortality.
Daniela Tomasoni	Italy	Retrospective study	Total sample are 692 patients	Between 1 March and 9 April 2020	Hospitalized patients with COVID-19 and a history of HF have an amazingly destitute result with higher mortality and in-hospital complications.	HF history is an free indicator of expanded in-hospital mortality.
JesusAlvarez-Garcia	USA	Retrospective study	Total sample are 6,439 patients	Between February 27, 2020, and June 26, 2020, and followed until October 7, 2020	As viral sicknesses such as flu have been detailed to accelerate unused HF, comparable theoretical relationships have been drawn with COVID-19. To the leading of our information, typically the largest consider to date to supply a setting for reports of new-onset HF within the setting of hospitalization for SARS-CoV2 contamination. We illustrate that, in spite of the fact that the point prevalence of modern HF is moo, a particular cohort of more youthful patients without cardiovascular hazard variables or malady involvement unused HF that will without a doubt be related to COVID-19.	The larger part of modern HF patients, in any case, had either CVRF or obvious CVD (stages A to B HF). Understanding particular components basic the sign of COVID-19 as unused HF warrants advance ponder.
Yishay Szekely	Israel	Retrospective study	Total sample 100 patients	Between March 21, 2020, and April 16, 2020	In COVID-19 contamination, LV systolic work is protected within the lion's share of patients, but LV diastolic work and RV work are impeded. Raised troponin and poorer clinical review are related with more regrettable RV work	In patients displaying with clinical disintegration at follow-up, intense RV brokenness, with or without profound vein thrombosis, is more common, but intense LV systolic brokenness was famous in ≈20%.

intercedes SARS-CoV-2 section into the have cells [62]. In this way, ACE2 may encourage organ harm by coordinate infection passage, with diverse clinical suggestions, concurring to the target organ. The infection, once interior the cell, employments host's Ribonucleic corrosive (RNA)-dependent RNA polymerase to imitate its possess auxiliary proteins and, when collected, modern infection is discharged from the cells; as a consequence, have cell can be damaged/destroyed in this prepare [5]. Reliably, SARS-CoV-2 inspiration in cardiac tissues can be reported in autoptic thinks about in continuous patients who kicked the bucket as a result of COVID-19 [63].

In expansion, ACE2 may be not as it were a straightforward bystander within the pathophysiology of myocardial harm: without a doubt, other than being the receptor of SARS-CoV-2, is an chemical included within the Renin–Angiotensin–Aldosterone Framework (RAAS). Once authoritative is total, the infection connects ACE2 throughout membrane combination and invagination, causing a downregulation within the movement of ACE2 [64,65]. Especially, ACE2 cleaves angiotensin II into angiotensin 1-7, which has vasodilating and anti-inflammatory impacts. ACE2 has moreover a frail partiality for angiotensin I and can change over it into the non-apeptide angiotensin 1-9, constraining angiotensin II union by Expert, and with vasodilatatory impacts through Angiotensin sort 2 (AT2) receptor incitement. Hence, ACE2 can check the untoward impacts of angiotensin II with vasodilatatory, antioxidant, and antifibrotic impacts [66]. ACE2 has too immuno-modulatory properties both coordinate, through its interaction with macrophages, and circuitous, diminishing angiotensin II which invigorates irritation [67]. ACE2 downregulation by SARS-CoV-2 contamination may increment angiotensin II levels, favoring AT1 receptor action, with a consequent vasoconstriction, fibrotic, proliferative, and proinflammatory impacts [68-69].

Heart failure as a result of COVID-19

Intense HF was found to be a conceivable result of COVID-19, with a emotional affect on mortality [26]. Amid COVID-19 hospitalization, approximately one-third of patients with past HF had an intense decompensation of HF [27]; in any case, intense HF can be created not as it were as a decompensation of incessant HF but too as a new-onset HF [28]. In an Italian multicenter think about, intense HF happened in 9.1% of patients amid hospitalization for COVID-19, and nearly half of them were "de-novo" HF in patients with no HF history [27]. Among 3,080 successive patients with affirmed COVID-19 contamination hospitalized in a tertiary center in Madrid (Spain), 2.5% of patients were analyzed with intense HF and endured from altogether higher mortality as compared with patients without HF(46.8 *vs.* 19.7%; $p < 0.001$) [70]. Arrhythmias amid healing center confirmation and constant HF were the most indicators of intense HF; be that as it may, 77.9% of intense HF did not have a past history of HF [70].

In COVID-19 patients displaying intense HF, LV systolic work isn't more often than not compromised; on the opposite, impedance of right ventricular (RV) systolic work and LV diastolic work can be found [71]. Out of 100 patients hospitalized for COVID-19, 32% were detailed to have typical echocardiography, though 39% displayed RV dilatation and brokenness and 16% LV diastolic brokenness, though decreased LV, EF was detailed as it were in < 10% [72]. Comparative comes about are portrayed in other little arrangement [73,74] and in a expansive universal cohort consider.

In like manner, LV diastolic impedance with lifted LV filling weights can be watched in a quarter of patients conceded for COVID-19 [74]. Reliably, patients hospitalized with COVID-19 appeared tall probability of nearness of HF with protected discharge division (HFpEF) as compared with patients without COVID-19 concurring to the score of the Heart FailureAffiliation (HFA) of the European Society of Cardiology (ESC), and HFpEF was found related with cardiac auxiliary and useful modifications and myocardial harm [75]. In addition, the longitudinal work can be disabled prior than LVEF: in a Danish imminent multicenter cohort ponder, no contrasts were found between cases and controls from the common populace with respect to LVEF; on the opposite, LV worldwide Longitudinal Strain (GLS) was essentially diminished [76]. Dot following was found to be able to recognize a decreased basal LV longitudinal strain in more than a half of hospitalized COVID-19 patients [77,78]. Additionally, RV systolic work [surveyed by RV longitudinal strain and Tricuspid Annular Plane Systolic Trip (TAPSE)] can be disabled in COVID-19 patients [79]. A more articulated lessening of cruel values of LV-GLS and RV longitudinal strain may well be found in extreme COVID-19 patients, and dot following investigation might foresee mortality indeed after altering for numerous confounders [79, 80].

CONCLUSSION

COVID-19 and HF have a solid association that go past pathophysiology. To begin with of all, COVID-19 widespread had an affect on HF hospitalization: a lessening on clinic affirmation for HF has been broadly portrayed, and this may have an affect on HF mortality. Moment, history of HF could be a visit comorbidity in patients hospitalized for COVID-19. It is related with a better mortality and more complications amid the clinical course, and this affiliation is free from other factors related with HF and COVID-19 severity. Third, we have appeared the tall predominance of cardiac harm taking after COVID-19 which is regularly analyzed as it were through biomarker estimations. Be that as it may, other than subclinical myocardial harm, SARS-CoV-2 contamination can cause myocarditis with a serious decrease of LVEF, or diastolic brokenness in a bigger number of patients. At last, HF may be a brief- or long-term result of COVID-19 provocative cardiomyopathy with a sensational result on the prognosis.

REFERENCES

1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020 Apr;5(4):536-544. doi: 10.1038/s41564-020-0695-z. Epub 2020 Mar 2. PMID: 32123347; PMCID: PMC7095448.
2. WHO. Coronavirus Disease (COVID-19) Dashboard. June 1, 2021. https://bit.ly/3LfkZKn
3. Tomasoni D, Italia L, Adamo M, Inciardi RM, Lombardi CM, Solomon SD, Metra M. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. Eur J Heart Fail. 2020 Jun;22(6):957-966. doi: 10.1002/ejhf.1871. Epub 2020 Jun 24. PMID: 32412156; PMCID: PMC7273093.
4. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5. PMID: 32139904; PMCID: PMC7095524.
5. Liu PP, Blet A, Smyth D, Li H. The Science Underlying COVID-19: Implications for the Cardiovascular System. Circulation. 2020 Jul 7;142(1):68-78. doi: 10.1161/CIRCULATIONAHA.120.047549. Epub 2020 Apr 15. PMID: 32293910.
6. Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020 May 14;41(19):1798-1800. doi: 10.1093/eurheartj/ehaa231. PMID: 32186331; PMCID: PMC7454513.
7. Solomon MD, McNulty EJ, Rana JS, Leong TK, Lee C, Sung SH, Ambrosy AP, Sidney S, Go AS. The Covid-19 Pandemic and the Incidence of Acute Myocardial Infarction. N Engl J Med. 2020 Aug 13;383(7):691-693. doi: 10.1056/NEJMc2015630. Epub 2020 May 19. PMID: 32427432.
8. Tomasoni D, Adamo M, Italia L, Branca L, Chizzola G, Fiorina C, Lupi L, Inciardi RM, Cani DS, Lombardi CM, Curello S, Metra M. Impact of COVID-2019 outbreak on prevalence, clinical presentation and outcomes of ST-elevation myocardial infarction. J Cardiovasc Med (Hagerstown). 2020 Nov;21(11):874-881. doi: 10.2459/JCM.0000000000001098. PMID: 32941325.
9. Bromage DI, Cannatà A, Rind IA, Gregorio C, Piper S, Shah AM, McDonagh TA. The impact of COVID-19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic. Eur J Heart Fail. 2020 Jun;22(6):978-984. doi: 10.1002/ejhf.1925. Epub 2020 Jul 4. PMID: 32478951; PMCID: PMC7300902.
10. Cox ZL, Lai P, Lindenfeld J. Decreases in acute heart failure hospitalizations during COVID-19. Eur J Heart Fail. 2020 Jun;22(6):1045-1046. doi: 10.1002/ejhf.1921. Epub 2020 Jul 2. PMID: 32469132; PMCID: PMC7283634.
11. Hall ME, Vaduganathan M, Khan MS, Papadimitriou L, Long RC, Hernandez GA, Moore CK, Lennep BW, McMullan MR, Butler J. Reductions in Heart Failure Hospitalizations During the COVID-19 Pandemic. J Card Fail. 2020 Jun;26(6):462-463. doi: 10.1016/j.cardfail.2020.05.005. Epub 2020 May 13. PMID: 32405232; PMCID: PMC7219367.
12. Cannatà A, Bromage DI, Rind IA, Gregorio C, Bannister C, Albarjas M, Piper S, Shah AM, McDonagh TA. Temporal trends in decompensated heart failure and outcomes during COVID-19: a multisite report from heart failure referral centres in London. Eur J Heart Fail. 2020 Dec;22(12):2219-2224. doi: 10.1002/ejhf.1986. Epub 2020 Sep 28. PMID: 32809274; PMCID: PMC7461082.
13. König S, Hohenstein S, Meier-Hellmann A, Kuhlen R, Hindricks G, Bollmann A; Helios Hospitals, Germany. In-hospital care in acute heart failure during the COVID-19 pandemic: insights from the German-wide Helios hospital network. Eur J Heart Fail. 2020 Dec;22(12):2190-2201. doi: 10.1002/ejhf.2044. Epub 2020 Dec 2. PMID: 33135851.
14. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, Wang T, Guo W, Chen J, Ding C, Zhang X, Huang J, Han M, Li S, Luo X, Zhao J, Ning Q. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020 Mar 26;368:m1091. doi: 10.1136/bmj.m1091. Erratum in: BMJ. 2020 Mar 31;368:m1295. PMID: 32217556; PMCID: PMC7190011.
15. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585. Erratum in: JAMA. 2021 Mar 16;325(11):1113. PMID: 32031570; PMCID: PMC7042881.
16. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu

T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24. Erratum in: Lancet Respir Med. 2020 Apr;8(4):e26. PMID: 32105632; PMCID: PMC7102538.

17. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. PMID: 32171076; PMCID: PMC7270627.

18. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30;: PMID: 31986264; PMCID: PMC7159299.

19. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, Tobin KA, Cerfolio RJ, Francois F, Horwitz LI. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020 May 22;369:m1966. doi: 10.1136/bmj.m1966. PMID: 32444366; PMCID: PMC7243801.

20. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; the Northwell COVID-19 Research Consortium, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020 May 26;323(20):2052-2059. doi: 10.1001/jama.2020.6775. Erratum in: JAMA. 2020 May 26;323(20):2098. PMID: 32320003; PMCID: PMC7177629.

21. Inciardi RM, Adamo M, Lupi L, Cani DS, Di Pasquale M, Tomasoni D, Italia L, Zaccone G, Tedino C, Fabbricatore D, Curnis A, Faggiano P, Gorga E, Lombardi CM, Milesi G, Vizzardi E, Volpini M, Nodari S, Specchia C, Maroldi R, Bezzi M, Metra M. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J. 2020 May 14;41(19):1821-1829. doi: 10.1093/eurheartj/ehaa388. Erratum in: Eur Heart J. 2020 Dec 21;41(48):4591. PMID: 32383763; PMCID: PMC7239204.

22. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648. PMID: 32091533.

23. Bae S, Kim SR, Kim MN, Shim WJ, Park SM. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis. Heart. 2021 Mar;107(5):373-380. doi: 10.1136/heartjnl-2020-317901. Epub 2020 Dec 17. PMID: 33334865; PMCID: PMC7747496.

24. Shi S, Qin M, Cai Y, Liu T, Shen B, Yang F, Cao S, Liu X, Xiang Y, Zhao Q, Huang H, Yang B, Huang C. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur Heart J. 2020 Jun 7;41(22):2070-2079. doi: 10.1093/eurheartj/ehaa408. PMID: 32391877; PMCID: PMC7239100.

25. Lala A, Johnson KW, Januzzi JL, Russak AJ, Paranjpe I, Richter F, Zhao S, Somani S, Van Vleck T, Vaid A, Chaudhry F, De Freitas JK, Fayad ZA, Pinney SP, Levin M, Charney A, Bagiella E, Narula J, Glicksberg BS, Nadkarni G, Mancini DM, Fuster V; Mount Sinai COVID Informatics Center. Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection. J Am Coll Cardiol. 2020 Aug 4;76(5):533-546. doi: 10.1016/j.jacc.2020.06.007. Epub 2020 Jun 8. PMID: 32517963; PMCID: PMC7279721.

26. Rey JR, Caro-Codón J, Rosillo SO, Iniesta ÁM, Castrejón-Castrejón S, Marco-Clement I, Martín-Polo L, Merino-Argos C, Rodríguez-Sotelo L, García-Veas JM, Martínez-Marín LA, Martínez-Cossiani M, Buño A, Gonzalez-Valle L, Herrero A, López-Sendón JL, Merino JL; CARD-COVID Investigators. Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications. Eur J Heart Fail. 2020 Dec;22(12):2205-2215. doi: 10.1002/ejhf.1990. Epub 2020 Oct 7. PMID: 32833283; PMCID: PMC7461427.

27. Tomasoni D, Inciardi RM, Lombardi CM, Tedino C, Agostoni P, Ameri P, Barbieri L, Bellasi A, Camporotondo R, Canale C, Carubelli V, Carugo S, Catagnano F, Dalla Vecchia LA, Danzi GB, Di Pasquale M, Gaudenzi M, Giovinazzo S, Gnecchi M, Iorio A, La Rovere MT, Leonardi S, Maccagni G, Mapelli M, Margonato D, Merlo M, Monzo L, Mortara A, Nuzzi V, Piepoli M, Porto I, Pozzi A, Sarullo F, Sinagra G, Volterrani M, Zaccone G, Guazzi M, Senni M, Metra M. Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study. Eur J Heart Fail. 2020 Dec;22(12):2238-2247. doi: 10.1002/ejhf.2052. Epub 2020 Nov 27. PMID: 33179839.

28. Alvarez-Garcia J, Lee S, Gupta A, Cagliostro M, Joshi AA, Rivas-Lasarte M, Contreras J, Mitter SS, LaRocca G, Tlachi P, Brunjes D, Glicksberg BS, Levin MA, Nadkarni G, Fayad Z, Fuster V, Mancini D, Lala A. Prognostic Impact of Prior Heart Failure in Patients Hospitalized With COVID-19. J Am Coll Cardiol. 2020 Nov 17;76(20):2334-2348. doi: 10.1016/j.jacc.2020.09.549. Epub 2020 Oct 28. PMID: 33129663; PMCID: PMC7598769.

29. Violi F, Cangemi R, Falcone M, Taliani G, Pieralli F, Vannucchi V, Nozzoli C, Venditti M, Chirinos JA, Corrales-Medina VF; SIXTUS (Thrombosis-Related Extrapulmonary Outcomes in Pneumonia) Study Group. Cardiovascular Complications and Short-term Mortality Risk in Community-Acquired Pneumonia. Clin Infect Dis. 2017 Jun 1;64(11):1486-1493. doi: 10.1093/cid/cix164. Erratum in: Clin Infect Dis. 2017 Oct 15;65(8):1431-1433. PMID: 28205683.

30. Madjid M, Miller CC, Zarubaev VV, Marinich IG, Kiselev OI, Lobzin YV, Filippov AE, Casscells SW 3rd. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects. Eur Heart J. 2007 May;28(10):1205-10. doi: 10.1093/eurheartj/ehm035. Epub 2007 Apr 17. PMID: 17440221; PMCID: PMC7108465.

31. Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang CC, Newman A, Loehr L, Folsom AR, Elkind MS, Lyles MF, Kronmal RA, Yende S. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015 Jan 20;313(3):264-74. doi: 10.1001/jama.2014.18229. PMID: 25602997; PMCID: PMC4687729.

32. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020 Jul;191:145-147. doi: 10.1016/j.thromres.2020.04.013. Epub 2020 Apr 10. PMID: 32291094; PMCID: PMC7146714.

33. de Roquetaillade C, Chousterman BG, Tomasoni D, Zeitouni M, Houdart E, Guedon A, Reiner P, Bordier R, Gayat E, Montalescot G, Metra M, Mebazaa A. Unusual arterial thrombotic events in Covid-19 patients. Int J Cardiol. 2021 Jan 15;323:281-284. doi: 10.1016/j.ijcard.2020.08.103. Epub 2020 Sep 10. PMID: 32918938; PMCID: PMC7481127.

34. Takasu O, Gaut JP, Watanabe E, To K, Fagley RE, Sato B, Jarman S, Efimov IR, Janks DL, Srivastava A, Bhayani SB, Drewry A, Swanson PE, Hotchkiss RS. Mechanisms of cardiac and renal dysfunction in patients dying of sepsis. Am J Respir Crit Care Med. 2013 Mar 1;187(5):509-17. doi: 10.1164/rccm.201211-1983OC. Epub 2013 Jan 24. PMID: 23348975; PMCID: PMC3733408.

35. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 Cytokine Storm; What We Know So Far. Front Immunol. 2020 Jun 16;11:1446. doi: 10.3389/fimmu.2020.01446. PMID: 32612617; PMCID: PMC7308649.

36. Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020 Dec 3;383(23):2255-2273. doi: 10.1056/NEJMra2026131. PMID: 33264547; PMCID: PMC7727315.

37. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz TH, Madduri D, Stock A, Marron TU, Xie H, Patel M, Tuballes K, Van Oekelen O, Rahman A, Kovatch P, Aberg JA, Schadt E, Jagannath S, Mazumdar M, Charney AW, Firpo-Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo C, Feldmann M, Parekh S, Merad M, Gnjatic S. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020 Oct;26(10):1636-1643. doi: 10.1038/s41591-020-1051-9. Epub 2020 Aug 24. PMID: 32839624; PMCID: PMC7869028.

38. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, Huang H, Yang B, Huang C. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020 Jul 1;5(7):802-810. doi: 10.1001/jamacardio.2020.0950. PMID: 32211816; PMCID: PMC7097841.

39. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Jul 1;5(7):811-818. doi: 10.1001/jamacardio.2020.1017. Erratum in: JAMA Cardiol. 2020 Jul 1;5(7):848. PMID: 32219356; PMCID: PMC7101506.

40. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16. PMID: 32192578; PMCID: PMC7270045.

41. Arévalos V, Ortega-Paz L, Rodríguez-Arias JJ, Calvo M, Castrillo L, Salazar A, Roque M, Dantas AP, Sabaté M, Brugaletta S. Myocardial Injury in COVID-19 Patients: Association with Inflammation, Coagulopathy and In-Hospital Prognosis. J Clin Med. 2021 May 13;10(10):2096. doi: 10.3390/jcm10102096. PMID: 34068127; PMCID: PMC8152726.

42. Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med. 1996 Mar 1;183(3):949-58. doi: 10.1084/jem.183.3.949. PMID: 8642298; PMCID: PMC2192364.

43. Kumar A, Brar R, Wang P, Dee L, Skorupa G, Khadour F, Schulz R, Parrillo JE. Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility. Am J Physiol. 1999 Jan;276(1):R265-76. doi: 10.1152/ajpregu.1999.276.1.R265. PMID: 9887205.

44. Joulin O, Petillot P, Labalette M, Lancel S, Neviere R. Cytokine profile of human septic shock serum inducing cardiomyocyte contractile dysfunction. Physiol Res. 2007;56(3):291-297. doi: 10.33549/physiolres.930946. Epub 2006 Jun 22. PMID: 16792475.

45. Unudurthi SD, Luthra P, Bose RJC, McCarthy JR, Kontaridis MI. Cardiac inflammation in COVID-19: Lessons from heart failure. Life Sci. 2020 Nov 1;260:118482. doi: 10.1016/j.lfs.2020.118482. Epub 2020 Sep 21. PMID: 32971105; PMCID: PMC7505073.

46. Markousis-Mavrogenis G, Tromp J, Ouwerkerk W, Devalaraja M, Anker SD, Cleland JG, Dickstein K, Filippatos GS, van der Harst P, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, Zannad F, Zwinderman AH, Hillege HL, van Veldhuisen DJ, Kakkar R, Voors AA, van der Meer P. The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study. Eur J Heart Fail. 2019 Aug;21(8):965-973. doi: 10.1002/ejhf.1482. Epub 2019 May 14. PMID: 31087601.

47. van der Pol A, van Gilst WH, Voors AA, van der Meer P. Treating oxidative stress in heart failure: past, present and future. Eur J Heart Fail. 2019 Apr;21(4):425-435. doi: 10.1002/ejhf.1320. Epub 2018 Oct 19. PMID: 30338885; PMCID: PMC6607515.

48. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020 May 2;395(10234):1417-1418. doi: 10.1016/S0140-6736(20)30937-5. Epub 2020 Apr 21. PMID: 32325026; PMCID: PMC7172722.

49. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A, Li WW, Li VW, Mentzer SJ, Jonigk D. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020 Jul 9;383(2):120-128. doi: 10.1056/NEJMoa2015432. Epub 2020 May 21. PMID: 32437596; PMCID: PMC7412750.

50. Gavriilaki E, Anyfanti P, Gavriilaki M, Lazaridis A, Douma S, Gkaliagkousi E. Endothelial Dysfunction in COVID-19: Lessons Learned from Coronaviruses. Curr Hypertens Rep. 2020 Aug 27;22(9):63. doi: 10.1007/s11906-020-01078-6. PMID: 32852642; PMCID: PMC7449866.

51. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17. PMID: 32678530; PMCID: PMC7383595.

52. Feldmann M, Maini RN, Woody JN, Holgate ST, Winter G, Rowland M, Richards D, Hussell T. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020 May 2;395(10234):1407-1409. doi: 10.1016/S0140-6736(20)30858-8. Epub 2020 Apr 9. PMID: 32278362; PMCID: PMC7158940.

53. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, Annane D, Azevedo LCP, Berwanger O, Cavalcanti AB, Dequin PF, Du B, Emberson J, Fisher D, Giraudeau B, Gordon AC, Granholm A, Green C, Haynes R, Heming N, Higgins JPT, Horby P, Jüni P, Landray MJ, Le Gouge A, Leclerc M, Lim WS, Machado FR, McArthur C, Meziani F, Møller MH, Perner A, Petersen MW, Savovic J, Tomazini B, Veiga VC, Webb S, Marshall JC. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020 Oct 6;324(13):1330-1341. doi: 10.1001/jama.2020.17023. PMID: 32876694; PMCID: PMC7489434.

54. Ameri P, Inciardi RM, Di Pasquale M, Agostoni P, Bellasi A, Camporotondo R, Canale C, Carubelli V, Carugo S, Catagnano F, Danzi G, Dalla Vecchia L, Giovinazzo S, Gnecchi M, Guazzi M, Iorio A, La Rovere MT, Leonardi S, Maccagni G, Mapelli M, Margonato D, Merlo M, Monzo L, Mortara A, Nuzzi V, Piepoli M, Porto I, Pozzi A, Provenzale G, Sarullo F, Sinagra G, Tedino C, Tomasoni D, Volterrani M, Zaccone G, Lombardi CM, Senni M, Metra M. Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study. Clin Res Cardiol. 2021 Jul;110(7):1020-1028. doi: 10.1007/s00392-020-01766-y. Epub 2020 Nov 3. PMID: 33141251; PMCID: PMC7607374.

55. Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. Science. 2020 Mar 27;367(6485):1412-1413. doi: 10.1126/science.367.6485.1412. PMID: 32217705.

56. Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM. Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature. Drug Saf. 2018 Oct;41(10):919-931. doi: 10.1007/s40264-018-0689-4. PMID: 29858838.

57. Tleyjeh IM, Kashour Z, AlDosary O, Riaz M, Tlayjeh H, Garbati MA, Tleyjeh R, Al-Mallah MH, Sohail MR, Gerberi D, Bin Abdulhak AA, Giudicessi JR, Ackerman MJ, Kashour T. Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis. Mayo Clin Proc Innov Qual Outcomes. 2021 Feb;5(1):137-150. doi: 10.1016/j.mayocpiqo.2020.10.005. Epub 2020 Nov 2. PMID: 33163895; PMCID: PMC7605861.

58. RECOVERY Collaborative Group, Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, Wiselka M, Ustianowski A, Elmahi E, Prudon B, Whitehouse T, Felton T, Williams J, Faccenda J, Underwood J, Baillie JK, Chappell LC, Faust SN, Jaki T, Jeffery K, Lim WS, Montgomery A, Rowan K, Tarning J, Watson JA, White NJ, Juszczak E, Haynes R, Landray MJ. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020 Nov 19;383(21):2030-2040. doi: 10.1056/NEJMoa2022926. Epub 2020 Oct 8. PMID: 33031652; PMCID: PMC7556338.

59. Nguyen LS, Dolladille C, Drici MD, Fenioux C, Alexandre J, Mira JP, Moslehi JJ, Roden DM, Funck-Brentano C, Salem JE. Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database. Circulation. 2020 Jul 21;142(3):303-305. doi: 10.1161/CIRCULATIONAHA.120.048238. Epub 2020 May 22. PMID: 32442023; PMCID: PMC7365677.

60. Varga ZV, Ferdinandy P, Liaudet L, Pacher P. Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol. 2015 Nov;309(9):H1453-67. doi: 10.1152/ajpheart.00554.2015. Epub 2015 Sep 18. PMID: 26386112; PMCID: PMC4666974.

61. Frattini S, Maccagni G, Italia L, Metra M, Danzi GB. Coronavirus disease 2019 and cardiovascular implications. J Cardiovasc Med (Hagerstown). 2020 Oct;21(10):725-732. doi: 10.2459/JCM.0000000000001068. PMID: 32858623.

62. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020 Mar 13;367(6483):1260-1263. doi: 10.1126/science.abb2507. Epub 2020 Feb 19. PMID: 32075877; PMCID: PMC7164637.

63. Lindner D, Fitzek A, Bräuninger H, Aleshcheva G, Edler C, Meissner K, Scherschel K, Kirchhof P, Escher F, Schultheiss HP, Blankenberg S, Püschel K, Westermann D. Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. JAMA Cardiol. 2020 Nov 1;5(11):1281-1285. doi: 10.1001/jamacardio.2020.3551. PMID: 32730555; PMCID: PMC7385672.

64. Bailey AL, Dmytrenko O, Greenberg L, Bredemeyer AL, Ma P, Liu J, Penna V, Winkler ES, Sviben S, Brooks E, Nair AP, Heck KA, Rali AS, Simpson L, Saririan M, Hobohm D, Stump WT, Fitzpatrick JA, Xie X, Zhang X, Shi PY, Hinson JT, Gi WT, Schmidt C, Leuschner F, Lin CY, Diamond MS, Greenberg MJ, Lavine KJ. SARS-CoV-2 Infects Human Engineered Heart Tissues and Models COVID-19 Myocarditis. JACC Basic Transl Sci. 2021 Apr;6(4):331-345. doi: 10.1016/j.jacbts.2021.01.002. Epub 2021 Feb 26. PMID: 33681537; PMCID: PMC7909907.

65. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020 Mar 27;367(6485):1444-1448. doi: 10.1126/science.abb2762. Epub 2020 Mar 4. PMID: 32132184; PMCID: PMC7164635.

66. Patel VB, Zhong JC, Grant MB, Oudit GY. Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure. Circ Res. 2016 Apr 15;118(8):1313-26. doi: 10.1161/CIRCRESAHA.116.307708. PMID: 27081112; PMCID: PMC4939482.

67. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. 2020 Jul 1;5(7):831-840. doi: 10.1001/jamacardio.2020.1286. PMID: 32219363.

68. Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol. 2020 May;31(5):1003-1008. doi: 10.1111/jce.14479. Epub 2020 Apr 13. PMID: 32270559; PMCID: PMC7262150.

69. Giustino G, Croft LB, Stefanini GG, Bragato R, Silbiger JJ, Vicenzi M, Danilov T, Kukar N, Shaban N, Kini A, Camaj A, Bienstock SW, Rashed ER, Rahman K, Oates CP, Buckley S, Elbaum LS, Arkonac D, Fiter R, Singh R, Li E, Razuk V, Robinson SE, Miller M, Bier B, Donghi V, Pisaniello M, Mantovani R, Pinto G, Rota I, Baggio S, Chiarito M, Fazzari F, Cusmano I, Curzi M, Ro R, Malick W, Kamran M, Kohli-Seth R, Bassily-Marcus AM, Neibart E, Serrao G, Perk G, Mancini D, Reddy VY, Pinney SP, Dangas G, Blasi F, Sharma SK, Mehran R, Condorelli G, Stone GW, Fuster V, Lerakis S, Goldman ME. Characterization of Myocardial Injury in Patients With COVID-19. J Am Coll Cardiol. 2020 Nov 3;76(18):2043-2055. doi: 10.1016/j.jacc.2020.08.069. PMID: 33121710; PMCID: PMC7588179.

70. Alvarez-Garcia J, Jaladanki S, Rivas-Lasarte M, Cagliostro M, Gupta A, Joshi A, Ting P, Mitter SS, Bagiella E, Mancini D, Lala A. New Heart Failure Diagnoses Among Patients Hospitalized for COVID-19. J Am Coll Cardiol. 2021 May 4;77(17):2260-2262. doi: 10.1016/j.jacc.2021.03.006. PMID: 33926664; PMCID: PMC8074874.

71. Szekely Y, Lichter Y, Taieb P, Banai A, Hochstadt A, Merdler I, Gal Oz A, Rothschild E, Baruch G, Peri Y, Arbel Y, Topilsky Y. Spectrum of Cardiac Manifestations in COVID-19: A Systematic Echocardiographic Study. Circulation. 2020 Jul 28;142(4):342-353. doi: 10.1161/CIRCULATIONAHA.120.047971. Epub 2020 May 29. PMID: 32469253; PMCID: PMC7382541.

72. Mahmoud-Elsayed HM, Moody WE, Bradlow WM, Khan-Kheil AM, Senior J, Hudsmith LE, Steeds RP. Echocardiographic Findings in Patients With COVID-19 Pneumonia. Can J Cardiol. 2020 Aug;36(8):1203-1207. doi: 10.1016/j.cjca.2020.05.030. Epub 2020 May 28. PMID: 32474111; PMCID: PMC7255734.

73. Schott JP, Mertens AN, Bloomingdale R, O'Connell TF, Gallagher MJ, Dixon S, Abbas AE. Transthoracic echocardiographic findings in patients admitted with SARS-CoV-2 infection. Echocardiography. 2020 Oct;37(10):1551-1556. doi: 10.1111/echo.14835. Epub 2020 Sep 19. PMID: 32949015; PMCID: PMC7537524.

74. Goerlich E, Metkus TS, Gilotra NA, Wu KC, Cingolani OH, Hays AG. Prevalence and Clinical Correlates of Echo-Estimated Right and Left Heart Filling Pressures in Hospitalized Patients With Coronavirus Disease 2019. Crit Care Explor. 2020 Sep 30;2(10):e0227. doi: 10.1097/CCE.0000000000000227. PMID: 33063031; PMCID: PMC7531757.

75. Hadzibegovic S, Lena A, Churchill TW, Ho JE, Potthoff S, Denecke C, Rösnick L, Heim KM, Kleinschmidt M, Sander LE, Witzenrath M, Suttorp N, Krannich A, Porthun J, Friede T, Butler J, Wilkenshoff U, Pieske B, Landmesser U, Anker SD, Lewis GD, Tschöpe C, Anker MS. Heart failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findings. Eur J Heart Fail. 2021 Nov;23(11):1891-1902. doi: 10.1002/ejhf.2210. Epub 2021 Jul 12. PMID: 33932255; PMCID: PMC8239668.

76. Lassen MCH, Skaarup KG, Lind JN, Alhakak AS, Sengeløv M, Nielsen AB, Espersen C, Ravnkilde K, Hauser R, Schöps LB, Holt E, Johansen ND, Modin D, Djernaes K, Graff C, Bundgaard H, Hassager C, Jabbari R, Carlsen J, Lebech AM, Kirk O, Bodtger U, Lindholm MG, Joseph G, Wiese L, Schiødt FV, Kristiansen OP, Walsted ES, Nielsen OW, Madsen BL, Tønder N, Benfield T, Jeschke KN, Ulrik CS, Knop FK, Lamberts M, Sivapalan P, Gislason G, Marott JL, Møgelvang R, Jensen G, Schnohr P, Søgaard P, Solomon SD, Iversen K, Jensen JUS, Schou M, Biering-Sørensen T. Echocardiographic abnormalities and predictors of mortality in hospitalized COVID-19 patients: the ECHOVID-19 study. ESC Heart Fail. 2020 Oct 22;7(6):4189–97. doi: 10.1002/ehf2.13044. Epub ahead of print. PMID: 33089972; PMCID: PMC7755011.

77. Goerlich E, Gilotra NA, Minhas AS, Bavaro N, Hays AG, Cingolani OH. Prominent Longitudinal Strain Reduction of Basal Left Ventricular Segments in Patients With Coronavirus Disease-19. J Card Fail. 2021 Jan;27(1):100-104. doi: 10.1016/j.cardfail.2020.09.469. Epub 2020 Sep 28. PMID: 32991982; PMCID: PMC7521413.

78. Stöbe S, Richter S, Seige M, Stehr S, Laufs U, Hagendorff A. Echocardiographic characteristics of patients with SARS-CoV-2 infection. Clin Res Cardiol. 2020 Dec;109(12):1549-1566. doi: 10.1007/s00392-020-01727-5. Epub 2020 Aug 14. PMID: 32803387; PMCID: PMC7428201.

79. Baycan OF, Barman HA, Atici A, Tatlisu A, Bolen F, Ergen P, Icten S, Gungor B, Caliskan M. Evaluation of biventricular function in patients with COVID-19 using speckle tracking echocardiography. Int J Cardiovasc Imaging. 2021 Jan;37(1):135-144. doi: 10.1007/s10554-020-01968-5. Epub 2020 Aug 15. PMID: 32803484; PMCID: PMC7429089.

80. Li Y, Li H, Zhu S, Xie Y, Wang B, He L, Zhang D, Zhang Y, Yuan H, Wu C, Sun W, Zhang Y, Li M, Cui L, Cai Y, Wang J, Yang Y, Lv Q, Zhang L, Xie M. Prognostic Value of Right Ventricular Longitudinal Strain in Patients With COVID-19. JACC Cardiovasc Imaging. 2020 Nov;13(11):2287-2299. doi: 10.1016/j.jcmg.2020.04.014. Epub 2020 Apr 28. PMID: 32654963; PMCID: PMC7195441.

81. Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol. 2012 Sep-Oct;21(5):365-71. doi: 10.1016/j.carpath.2011.11.007. Epub 2012 Jan 5. PMID: 22227365.